1-9 of 9
waldenstrom macroglobulinemia
Close
Sort by
Journal Articles

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia

Clinical Trials & Observations
Cécile Tomowiak, Stéphanie Poulain, Charles Herbaux, Aurore Perrot, Béatrice Mahé, Pierre Morel, Thérèse Aurran, Olivier Tournilhac, Stéphane Leprêtre, Souad Assaad, Bruno Villemagne, Olivier Casasnovas, Delphine Nollet, Damien Roos-Weil, Sylvie Chevret, Véronique Leblond
Journal: Blood Advances
Blood Adv (2021) 5 (9): 2438–2446.
https://doi.org/10.1182/bloodadvances.2020003895
Published: 2021
Includes: Supplemental data
Journal Articles

Comparative genomics of CXCR4 MUT and CXCR4 WT single cells in Waldenström’s macroglobulinemia

Cristina Jiménez, Lian Xu, Nickolas Tsakmaklis, Maria G. Demos, Amanda Kofides, Gloria G. Chan, Maria Luisa Guerrera, Jiaji G. Chen, Xia Liu, Manit Munshi, Christopher J. Patterson, Guang Yang, Jorge J. Castillo, Steven P. Treon, Zachary R. Hunter
Journal: Blood Advances
Blood Adv (2020) 4 (18): 4550–4553.
https://doi.org/10.1182/bloodadvances.2020001775
Published: 2020
Includes: Supplemental data
Journal Articles

Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up

Clinical Trials & Observations
Jorge J. Castillo, Kirsten Meid, Catherine A. Flynn, Jiaji Chen, Maria G. Demos, Maria L. Guerrera, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Christopher J. Patterson, Guang Yang, Zachary Hunter, Steven P. Treon
Journal: Blood Advances
Blood Adv (2020) 4 (16): 3952–3959.
https://doi.org/10.1182/bloodadvances.2020001963
Published: 2020
Journal Articles

TLR-mediated activation of Waldenström macroglobulinemia B cells reveals an uncoupling from plasma cell differentiation

Jennifer Shrimpton, Matthew A. Care, Jonathan Carmichael, Kieran Walker, Paul Evans, Charlotte Evans, Ruth de Tute, Roger Owen, Reuben M. Tooze, Gina M. Doody
Journal: Blood Advances
Blood Adv (2020) 4 (12): 2821–2836.
https://doi.org/10.1182/bloodadvances.2019001279
Published: 2020
Includes: Supplemental data
Journal Articles

CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia

Joshua N. Gustine, Lian Xu, Nicholas Tsakmaklis, Maria G. Demos, Amanda Kofides, Jiaji G. Chen, Xia Liu, Manit Munshi, Maria Luisa Guerrera, Gloria G. Chan, Christopher J. Patterson, Andrew Keezer, Kirsten Meid, Toni Dubeau, Guang Yang, Zachary R. Hunter, Steven P. Treon, Jorge J. Castillo
Journal: Blood Advances
Blood Adv (2019) 3 (19): 2800–2803.
https://doi.org/10.1182/bloodadvances.2019000635
Published: 2019
Includes: Supplemental data
Journal Articles

Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia

Clinical Trials & Observations
Stephanie Guidez, Julien Labreuche, Elodie Drumez, Loic Ysebaert, Jana Bakala, Caroline Delette, Bénédicte Hivert, Caroline Protin, Hervé Declercq, Mélanie Verlay, Jean Pierre Marolleau, Alain Duhamel, Pierre Morel
Journal: Blood Advances
Blood Adv (2018) 2 (22): 3102–3111.
https://doi.org/10.1182/bloodadvances.2018021287
Published: 2018
Includes: Supplemental data
Journal Articles

Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia

Clinical Trials & Observations
Zachary R. Hunter, Lian Xu, Nickolas Tsakmaklis, Maria G. Demos, Amanda Kofides, Cristina Jimenez, Gloria G. Chan, Jiaji Chen, Xia Liu, Manit Munshi, Joshua Gustine, Kirsten Meid, Christopher J. Patterson, Guang Yang, Toni Dubeau, Mehmet K. Samur, Jorge J. Castillo, Kenneth C. Anderson, Nikhil C. Munshi, Steven P. Treon
Journal: Blood Advances
Blood Adv (2018) 2 (21): 2937–2946.
https://doi.org/10.1182/bloodadvances.2018022962
Published: 2018
Includes: Supplemental data
Journal Articles

Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia

Shahrzad Jalali, Tammy Price-Troska, Jonas Paludo, Jose Villasboas, Hyo-Jin Kim, Zhi-Zhang Yang, Anne J. Novak, Stephen M. Ansell
Journal: Blood Advances
Blood Adv (2018) 2 (15): 1985–1997.
https://doi.org/10.1182/bloodadvances.2018021113
Published: 2018
Journal Articles

What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy

Clinical Trials & Observations
Steven P. Treon, Jorge J. Castillo
Journal: Blood Advances
Blood Adv (2017) 1 (25): 2486–2490.
https://doi.org/10.1182/bloodadvances.2017005637
Published: 2017